Eisai's Eribulin (Halaven(R)) Receives Swissmedic Approval for use in Locally Advanced and Metastatic Breast Cancer (y 2

Eisai is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs approximately 11,000 employees worldwide.

For further information, please visit http://www.eisai.co.jp.

* Eribulin-mesylate is indicated for the treatment of patients with locally advanced or metastatic breast cancer that has progressed after prior anthracycline, taxane, and capecitabine therapy. ---------------------------------

[1] Swiss medic approval letter

[2] Sources: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]

[3] http://globocan.iarc.fr/factsheets/popul...

[4] Cortes J, O'Shaughnessy J, Loesch D, et al. A Phase III open-label randomized study (EMBRACE) or eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer. The Lancet. 2011; 377: 914 -923

[5] Kuznetsov G, Towle MJ, Cheng H, et al: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760-5766

[6] Towle MJ, et al. In Vitro and In Vivo Anticancer Activities of Synthetic Macrocyclic Ketone Analogues of Halichondrin B. Cancer Res 2001; 61: 1013-1021

[7] Cortes et al. Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. Jour Clin Oncol, September 1, 2010 vol. 28 no. 25 3922-3928.

[8] Coughlin, S. Breast cancer as a global health concern. Cancer Epidemiology, October 2009; 33: 315-18.

[9] Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer.2010: 46(4):765-781

[10] O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-29

[11] Cancer Research UK, Breast Cancer Statistics - Key Facts [updated April 2010]. Available from: http://info.cancerresearchuk.org/cancers... (accessed (04/08/10)

[12] Fernandez Y, Cueva J, Palomo AG, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev.2010:36(1):33-42

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson,+44-7908-314-155, Cressida_Robson@eisai.net